Citadel Advisors’s TrovaGene, Inc. Warrant TROVW Stock Holding History

Citadel Advisors’s Portfolio TROVW Stock Details TROVW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-34,500	Closed	-$156K	–	8150
2016 Q2	$156K	Buy	34,500 +18,400	+114%	+$56.5K	﹤0.01%	6001
2016 Q1	$75K	Buy	16,100 +5,700	+55%	+$18.5K	﹤0.01%	6144
2015 Q4	$56K	Buy	+10,400	New	+$35.8K	﹤0.01%	7227
2015 Q3	–	Sell	-20,300	Closed	-$206K	–	9481
2015 Q2	$206K	Buy	+20,300	New	+$130K	﹤0.01%	6283

Other funds holding TROVW

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's TROVW Position: Q3 2015 in Review

Citadel Advisors sold out of TrovaGene, Inc. Warrant (TROVW) in Q3 2015, closing a stake of 200 shares — an estimated $1K sold.

Citadel Advisors first reported a position in TROVW in Q2 2015 and held it in 1 quarter. The position peaked at $1K in Q2 2015. 3 funds tracked by Wall St. Rank hold TROVW as of Q3 2015.

Citadel Advisors reported no remaining TrovaGene, Inc. Warrant position as of Q3 2015 after selling out during the quarter.
Citadel Advisors sold 200 TrovaGene, Inc. Warrant shares in Q3 2015, an estimated $1K.
Citadel Advisors first reported a position in TrovaGene, Inc. Warrant in Q2 2015 and held it in 1 quarter.
Citadel Advisors's TrovaGene, Inc. Warrant position peaked at $1K in Q2 2015.
3 funds tracked by Wall St. Rank held TrovaGene, Inc. Warrant as of Q3 2015.

Based on Citadel Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.